Loading patent…
AssigneesUniversity of Massachusetts, Rush University Medical Center
InventorsJoel D. Richter, Sneha Shah, Elizabeth Berry-Kravis
Estimating the term…
Provided herein, in various embodiments, are methods of diagnosing a subject as having, or having a propensity to develop, a fragile X-associated disorder (e.g., FXS), methods of prognosing a fragile X-associated disorder (e.g., FXS) in a subject, methods of predicting a treatment outcome of a fragile X-associated disorder (e.g., FXS) in a subject, methods of stratifying a set of subjects having a fragile X-associated disorder, methods of stratifying a population of subjects having, or having a propensity to develop, FXS, and method for assessing the efficacy of a drug for treatment of FXS. Also provided herein, in various embodiments, are assays and systems useful for performing the disclosed methods. The present disclosure also provides methods of treating a subject having FXS.
A method of diagnosing a subject as having, or having a propensity to develop, a fragile X-associated disorder, comprising assaying at least one RNA biomarker in a biological sample from the subject, wherein the level and/or splicing of the at least one RNA biomarker in the biological sample is indicative of the subject as having, or having a propensity to develop, the fragile X-associated disorder, and wherein the biological sample is a non-neural biological sample.
A method of predicting a treatment outcome of a fragile X-associated disorder in a subject, comprising assaying at least one RNA biomarker in a biological sample from the subject, wherein the level and/or splicing of the at least one RNA biomarker in the biological sample is indicative of the subject having a propensity to have a poorer treatment outcome, and wherein the biological sample is a non-neural biological sample.
A system, comprising one or more polynucleotide probes and/or one or more polynucleotide primers configured to detect, in a biological sample, the level and/or splicing of the at least one RNA biomarker associated with fragile X-associated disorder.
Dependencies are inferred from the claim text.